Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ hybridization in invasive breast cancer: A single institution study

Sarah Lee, Woohee Jung, Soon Won Hong, Ja Seung Koo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This study aimed to determine the incidence and characteristics of HER-2 gene heterogeneity in invasive breast cancer in a single institution. Included were 971 cases of primary invasive breast cancer diagnosed between 2008 and 2010. Fluorescence in situ hybridization (FISH) image files were retrospectively reviewed and HER-2 gene heterogeneity was defined as more than 5% but less than 50% of analyzed invasive tumor cells with a HER-2/Chr17 ratio higher than 2.2, according to the College of American Pathologists guidelines. HER-2 gene heterogeneity was identified in 24 (2.5%) cases. The mean proportion of invasive tumor cells with a HER-2/chromosome 17 ratio higher than 2.2 was 11.6% (range: 5%-25%). Of 24 cases, HER-2 gene status was not amplified in 8, showed borderline amplification in 2, and amplification in 14. All HER-2 amplification cases were low-grade. In conclusion, HER-2 gene heterogeneity of invasive breast cancer is identified in routine FISH examination. This may affect the results of HER-2 gene amplification status in FISH studies.

Original languageEnglish
Pages (from-to)1001-1006
Number of pages6
JournalJournal of Korean medical science
Volume26
Issue number8
DOIs
Publication statusPublished - 2011 Aug 1

Fingerprint

erbB-2 Genes
Fluorescence In Situ Hybridization
Breast Neoplasms
Chromosomes, Human, Pair 17
Gene Amplification
Neoplasms
Guidelines
Incidence

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{7354ba37618847f68117cd5a451cb8a0,
title = "Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ hybridization in invasive breast cancer: A single institution study",
abstract = "This study aimed to determine the incidence and characteristics of HER-2 gene heterogeneity in invasive breast cancer in a single institution. Included were 971 cases of primary invasive breast cancer diagnosed between 2008 and 2010. Fluorescence in situ hybridization (FISH) image files were retrospectively reviewed and HER-2 gene heterogeneity was defined as more than 5{\%} but less than 50{\%} of analyzed invasive tumor cells with a HER-2/Chr17 ratio higher than 2.2, according to the College of American Pathologists guidelines. HER-2 gene heterogeneity was identified in 24 (2.5{\%}) cases. The mean proportion of invasive tumor cells with a HER-2/chromosome 17 ratio higher than 2.2 was 11.6{\%} (range: 5{\%}-25{\%}). Of 24 cases, HER-2 gene status was not amplified in 8, showed borderline amplification in 2, and amplification in 14. All HER-2 amplification cases were low-grade. In conclusion, HER-2 gene heterogeneity of invasive breast cancer is identified in routine FISH examination. This may affect the results of HER-2 gene amplification status in FISH studies.",
author = "Sarah Lee and Woohee Jung and Hong, {Soon Won} and Koo, {Ja Seung}",
year = "2011",
month = "8",
day = "1",
doi = "10.3346/jkms.2011.26.8.1001",
language = "English",
volume = "26",
pages = "1001--1006",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "8",

}

Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ hybridization in invasive breast cancer : A single institution study. / Lee, Sarah; Jung, Woohee; Hong, Soon Won; Koo, Ja Seung.

In: Journal of Korean medical science, Vol. 26, No. 8, 01.08.2011, p. 1001-1006.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ hybridization in invasive breast cancer

T2 - A single institution study

AU - Lee, Sarah

AU - Jung, Woohee

AU - Hong, Soon Won

AU - Koo, Ja Seung

PY - 2011/8/1

Y1 - 2011/8/1

N2 - This study aimed to determine the incidence and characteristics of HER-2 gene heterogeneity in invasive breast cancer in a single institution. Included were 971 cases of primary invasive breast cancer diagnosed between 2008 and 2010. Fluorescence in situ hybridization (FISH) image files were retrospectively reviewed and HER-2 gene heterogeneity was defined as more than 5% but less than 50% of analyzed invasive tumor cells with a HER-2/Chr17 ratio higher than 2.2, according to the College of American Pathologists guidelines. HER-2 gene heterogeneity was identified in 24 (2.5%) cases. The mean proportion of invasive tumor cells with a HER-2/chromosome 17 ratio higher than 2.2 was 11.6% (range: 5%-25%). Of 24 cases, HER-2 gene status was not amplified in 8, showed borderline amplification in 2, and amplification in 14. All HER-2 amplification cases were low-grade. In conclusion, HER-2 gene heterogeneity of invasive breast cancer is identified in routine FISH examination. This may affect the results of HER-2 gene amplification status in FISH studies.

AB - This study aimed to determine the incidence and characteristics of HER-2 gene heterogeneity in invasive breast cancer in a single institution. Included were 971 cases of primary invasive breast cancer diagnosed between 2008 and 2010. Fluorescence in situ hybridization (FISH) image files were retrospectively reviewed and HER-2 gene heterogeneity was defined as more than 5% but less than 50% of analyzed invasive tumor cells with a HER-2/Chr17 ratio higher than 2.2, according to the College of American Pathologists guidelines. HER-2 gene heterogeneity was identified in 24 (2.5%) cases. The mean proportion of invasive tumor cells with a HER-2/chromosome 17 ratio higher than 2.2 was 11.6% (range: 5%-25%). Of 24 cases, HER-2 gene status was not amplified in 8, showed borderline amplification in 2, and amplification in 14. All HER-2 amplification cases were low-grade. In conclusion, HER-2 gene heterogeneity of invasive breast cancer is identified in routine FISH examination. This may affect the results of HER-2 gene amplification status in FISH studies.

UR - http://www.scopus.com/inward/record.url?scp=80052658299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052658299&partnerID=8YFLogxK

U2 - 10.3346/jkms.2011.26.8.1001

DO - 10.3346/jkms.2011.26.8.1001

M3 - Article

C2 - 21860549

AN - SCOPUS:80052658299

VL - 26

SP - 1001

EP - 1006

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 8

ER -